Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod IV in adolescents with chronic primary immune thrombocytopenia
2025-521055-23-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Oct 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa in immune thrombocytopenia (ITP) and chronic primary immune thrombocytopenia (ITP) (3 arms), sponsored by argenx. Planned start Oct 2025; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2025-521055-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521055-23-00.